vs
EVERTEC, Inc.（EVTC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
EVERTEC, Inc.的季度营收约是再鼎医药的1.9倍（$244.8M vs $127.1M），再鼎医药同比增速更快（17.1% vs 13.1%），EVERTEC, Inc.自由现金流更多（$63.7M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 9.2%）
EVERTEC Inc.是总部位于波多黎各的领先全品类支付技术与交易处理服务商，主要面向拉丁美洲及加勒比地区的金融机构、零售商户和政府客户，提供商户收单、电子资金转账、数字支付解决方案及业务流程外包服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
EVTC vs ZLAB — 直观对比
营收规模更大
EVTC
是对方的1.9倍
$127.1M
营收增速更快
ZLAB
高出4.0%
13.1%
自由现金流更多
EVTC
多$90.4M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
9.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $244.8M | $127.1M |
| 净利润 | $37.0M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 17.6% | -54.6% |
| 净利率 | 15.1% | — |
| 营收同比 | 13.1% | 17.1% |
| 净利润同比 | -8.9% | — |
| 每股收益（稀释后） | $0.57 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EVTCZLAB
| Q4 25 | $244.8M | $127.1M | ||
| Q3 25 | $228.6M | $115.4M | ||
| Q2 25 | $229.6M | $109.1M | ||
| Q1 25 | $228.8M | $105.7M | ||
| Q4 24 | $216.4M | $108.5M | ||
| Q3 24 | $211.8M | $101.8M | ||
| Q2 24 | $212.0M | $100.1M | ||
| Q1 24 | $205.3M | $87.1M |
净利润EVTCZLAB
| Q4 25 | $37.0M | — | ||
| Q3 25 | $32.9M | $-36.0M | ||
| Q2 25 | $40.5M | $-40.7M | ||
| Q1 25 | $32.7M | $-48.4M | ||
| Q4 24 | $40.7M | — | ||
| Q3 24 | $24.7M | $-41.7M | ||
| Q2 24 | $31.9M | $-80.3M | ||
| Q1 24 | $16.0M | $-53.5M |
毛利率EVTCZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率EVTCZLAB
| Q4 25 | 17.6% | -54.6% | ||
| Q3 25 | 16.5% | -42.3% | ||
| Q2 25 | 24.4% | -50.3% | ||
| Q1 25 | 21.6% | -53.3% | ||
| Q4 24 | 22.2% | -62.6% | ||
| Q3 24 | 19.6% | -66.6% | ||
| Q2 24 | 20.5% | -76.0% | ||
| Q1 24 | 16.0% | -80.7% |
净利率EVTCZLAB
| Q4 25 | 15.1% | — | ||
| Q3 25 | 14.4% | -31.2% | ||
| Q2 25 | 17.6% | -37.3% | ||
| Q1 25 | 14.3% | -45.8% | ||
| Q4 24 | 18.8% | — | ||
| Q3 24 | 11.7% | -40.9% | ||
| Q2 24 | 15.0% | -80.2% | ||
| Q1 24 | 7.8% | -61.4% |
每股收益（稀释后）EVTCZLAB
| Q4 25 | $0.57 | $-0.05 | ||
| Q3 25 | $0.51 | $-0.03 | ||
| Q2 25 | $0.62 | $-0.04 | ||
| Q1 25 | $0.50 | $-0.04 | ||
| Q4 24 | $0.62 | $-0.09 | ||
| Q3 24 | $0.38 | $-0.04 | ||
| Q2 24 | $0.49 | $-0.08 | ||
| Q1 24 | $0.24 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $306.0M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $621.6M | $715.5M |
| 总资产 | $2.2B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EVTCZLAB
| Q4 25 | $306.0M | $689.6M | ||
| Q3 25 | $474.7M | $717.2M | ||
| Q2 25 | $290.6M | $732.2M | ||
| Q1 25 | $265.9M | $757.3M | ||
| Q4 24 | $273.6M | $779.7M | ||
| Q3 24 | $275.4M | $616.1M | ||
| Q2 24 | $257.7M | $630.0M | ||
| Q1 24 | $293.7M | $650.8M |
股东权益EVTCZLAB
| Q4 25 | $621.6M | $715.5M | ||
| Q3 25 | $663.8M | $759.9M | ||
| Q2 25 | $612.3M | $791.7M | ||
| Q1 25 | $542.1M | $810.8M | ||
| Q4 24 | $472.5M | $840.9M | ||
| Q3 24 | $502.6M | $667.7M | ||
| Q2 24 | $483.4M | $704.2M | ||
| Q1 24 | $507.3M | $762.2M |
总资产EVTCZLAB
| Q4 25 | $2.2B | $1.2B | ||
| Q3 25 | $2.1B | $1.2B | ||
| Q2 25 | $2.0B | $1.2B | ||
| Q1 25 | $1.9B | $1.2B | ||
| Q4 24 | $1.9B | $1.2B | ||
| Q3 24 | $1.9B | $985.3M | ||
| Q2 24 | $1.9B | $987.4M | ||
| Q1 24 | $2.0B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $70.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $63.7M | $-26.7M |
| 自由现金流率自由现金流/营收 | 26.0% | -21.0% |
| 资本支出强度资本支出/营收 | 2.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.89× | — |
| 过去12个月自由现金流最近4个季度 | $203.7M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流EVTCZLAB
| Q4 25 | $70.0M | $-26.0M | ||
| Q3 25 | $70.9M | $-32.0M | ||
| Q2 25 | $48.5M | $-31.0M | ||
| Q1 25 | $37.6M | $-61.7M | ||
| Q4 24 | $75.2M | $-55.8M | ||
| Q3 24 | $53.6M | $-26.8M | ||
| Q2 24 | $90.6M | $-42.2M | ||
| Q1 24 | $40.7M | $-90.1M |
自由现金流EVTCZLAB
| Q4 25 | $63.7M | $-26.7M | ||
| Q3 25 | $65.3M | $-35.0M | ||
| Q2 25 | $43.5M | $-33.9M | ||
| Q1 25 | $31.2M | $-63.2M | ||
| Q4 24 | $70.8M | $-58.4M | ||
| Q3 24 | $49.7M | $-28.2M | ||
| Q2 24 | $78.8M | $-42.9M | ||
| Q1 24 | $35.3M | $-91.1M |
自由现金流率EVTCZLAB
| Q4 25 | 26.0% | -21.0% | ||
| Q3 25 | 28.5% | -30.4% | ||
| Q2 25 | 18.9% | -31.1% | ||
| Q1 25 | 13.7% | -59.9% | ||
| Q4 24 | 32.7% | -53.8% | ||
| Q3 24 | 23.5% | -27.7% | ||
| Q2 24 | 37.2% | -42.9% | ||
| Q1 24 | 17.2% | -104.5% |
资本支出强度EVTCZLAB
| Q4 25 | 2.6% | 0.5% | ||
| Q3 25 | 2.5% | 2.6% | ||
| Q2 25 | 2.2% | 2.6% | ||
| Q1 25 | 2.8% | 1.5% | ||
| Q4 24 | 2.0% | 2.4% | ||
| Q3 24 | 1.8% | 1.3% | ||
| Q2 24 | 5.6% | 0.7% | ||
| Q1 24 | 2.6% | 1.1% |
现金转化率EVTCZLAB
| Q4 25 | 1.89× | — | ||
| Q3 25 | 2.16× | — | ||
| Q2 25 | 1.20× | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 1.85× | — | ||
| Q3 24 | 2.17× | — | ||
| Q2 24 | 2.84× | — | ||
| Q1 24 | 2.55× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EVTC
| Latin America Payments And Solutions | $101.5M | 41% |
| Business Solutions | $58.3M | 24% |
| Merchant Acquiring Net | $48.2M | 20% |
| Payment Services Puerto Rico Caribbean | $36.8M | 15% |
| Transferred At Point In Time | $4.0M | 2% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
